Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOASIS: Neoadjuvant Botensilimab and Balstilimab in Solid Tumors
NCT06279130Phase 3Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2024
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of botensilimab, balstilimab in solid tumor, sponsored by Netherlands Cancer Institute. Started Jan 2024; status: recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06279130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06279130.